New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:32 EDTANAC, SPPIAnacor appoints Paul L. Berns as CEO, effective immediately
Berns succeeds David P. Perry who has served as Anacorís (ANAC) President and CEO since 2002. Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies. He most recently served as the President and Chief Executive Officer of Allos Therapeutics prior to its acquisition by Spectrum Pharmaceuticals (SPPI) in 2012.
News For ANAC;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
11:15 EDTANACAnacor management to meet with Jefferies
Subscribe for More Information
August 21, 2015
08:10 EDTANACAnacor: Coalition seeks to invalidate patents for Kerydin
In a regulatory filing, Anacor said that on August 20, a hedge fund -- acting with affiliated parties and proceeding under the name of the Coalition for Affordable Drugs X LLC -- filed petitions with the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office seeking to institute inter partes review proceedings to invalidate Anacor Pharmaceuticals, Inc.'s Orange Book-listed U.S. Patents Nos. 7,582,621 and 7,767,657 covering KERYDIN topical solution, 5%.If one or more of CFAD's IPR petitions are accepted by the PTAB, the Company will have three months to file its preliminary responses. Upon receipt of the Company's preliminary responses, the PTAB will have another three months in which to institute or deny the IPR proceedings. If the IPR proceedings are instituted by the PTAB, CFAD will have an opportunity to challenge the validity of some or all of the claims in the Kerydin Orange Book Patents before the PTAB. The Company is currently reviewing CFAD's IPR petitions and intends to vigorously oppose the institution of the IPR proceedings and, if the IPR proceedings are instituted, to vigorously defend the Kerydin Orange Book Patents.
August 17, 2015
07:04 EDTSPPISpectrum announces FDA on SPA for upcoming Apaziquone Phase 3 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use